<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03578042</url>
  </required_header>
  <id_info>
    <org_study_id>Losanet AM Plus trial</org_study_id>
    <nct_id>NCT03578042</nct_id>
  </id_info>
  <brief_title>Fixed-Free HTN Trial</brief_title>
  <official_title>Effect of Fixed Triple Combination With Losartan-Amlodipin-HCTZ vs. Free Triple Combination on Blood Pressure Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hotel Dieu de France Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hotel Dieu de France Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the effect of FIXED triple anti-hypertensive therapy with
      losartan-amlodipin-HCTZ vs any free triple combination therapy chosen by the treating
      physician for patients with uncontrolled hypertension
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have uncontrolled hypertension and who require triple therapy will be randomized
      to receive:

        1. Fixed combination containing 3 anti-hypertensive drugs: losartan 100 mg + amlodipin 5 mg
           + hydrocholorothiazide 12.5 mg one tab/day

        2. Or any other therapy decided by the treating physician containing three
           anti-hypertensive agents but supplied as &quot;free&quot; therapy, meaning supplied as 2 or 3
           separate tablets Patients will have a baseline ambulatory blood pressure recording. The
           same recording will be repeated at 2 months of therapy.

      We expect fixed triple combination to be more effective because the drugs used work
      synergistically together and the compliance will be higher
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>average 24 hour blood pressure measured by ambulatory recording</measure>
    <time_frame>measured after 2 months of therapy</time_frame>
    <description>Measured by ambulatory blood pressure recording over 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>central aortic blood pressure</measure>
    <time_frame>measured after 2 months of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulse wave velocity</measure>
    <time_frame>measured after 2 months of therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>LosanetAMplus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients taking the fixed triple combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients taking 2 or 3 free combinations containing 3 drugs for hypertension as decided by the treating physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan and amlodipine and hydrochlorothiazide</intervention_name>
    <description>this is a fixed combination containing the 3 drugs</description>
    <arm_group_label>LosanetAMplus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>any free triple combination therapy for hypertension given as 2 or 3 pills</description>
    <arm_group_label>standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients already on free triple anti-HTN therapy whether controlled or not Or patients
             on double anti-HTN therapy who are uncontrolled* Or patients on monotherapy and who
             have a BP &gt; 160/100 mm Hg

               -  BP is defined as UNCONTROLLED if &gt; 135/85 at home or &gt; 140/90 in clinic on at
                  least 2 occasions

        Exclusion Criteria:

          -  Contra-indication for the use of ARB or ACEI, CCB or hydrochlorothiazide History of
             angina pectoris or myocardial infarction &lt; 3 months old Permanent atrial fibrillation
             Ejection fraction &lt; 40% Patients with hypertension but who are not on any medication
             Patients with hypertension and who are treated with &gt; 3 drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rabih R Azar, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hotel Dieu de France Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rabih R Azar, MD, MPH</last_name>
    <phone>+9611615300</phone>
    <phone_ext>9418</phone_ext>
    <email>razar@usj.edu.lb</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hotel Dieu de France Hospital</name>
      <address>
        <city>Beirut</city>
        <zip>Beirut</zip>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rabih R Azar, MD, MPH</last_name>
      <phone>+9611615300</phone>
      <phone_ext>9408</phone_ext>
      <email>razar@usj.edu.lb</email>
    </contact>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>June 24, 2018</last_update_submitted>
  <last_update_submitted_qc>June 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hotel Dieu de France Hospital</investigator_affiliation>
    <investigator_full_name>Rabih Azar</investigator_full_name>
    <investigator_title>MD, MPH, Chief of Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

